BEST UNLIMITED TURBO LONG CERTIFICATE - ELI LILLY & CO | Real-time Euronext Paris 08:13:07 28/06/2024 BST | ||
| 29.31 EUR | +1.74% |
|
| Current month | +17.72% | ||
| 1 month | +18.62% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 29.31 | +1.74% |
| 27/06/24 | 28.81 | -0.46% |
| 26/06/24 | 28.94 | +0.74% |
| 25/06/24 | 28.73 | +0.43% |
| 24/06/24 | 28.61 | +1.90% |
Real-time Euronext Paris
Last update June 28, 2024 at 08:13 am
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| BE81S | |
| ISIN | DE000SH8J774 |
| Date issued | 08/04/2022 |
| Strike | 289.3 $ |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | 2.91 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 29.31 € |
|---|---|
| Lowest since issue | 1.599 € |
| Spread | 0.138 € |
| Spread % | 0.47% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
909
USD
Average target price
860.5
USD
Spread / Average Target
-5.33%
- Stock Market
- Certificates
- BE81S Certificat
